Curis Company Profile (NASDAQ:CRIS)

About Curis

Curis logoCuris, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CRIS
  • CUSIP: 23126910
Key Metrics:
  • Previous Close: $2.61
  • 50 Day Moving Average: $1.94
  • 200 Day Moving Average: $1.78
  • 52-Week Range: $1.25 - $3.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.22
  • P/E Growth: 0.00
  • Market Cap: $337.92M
  • Outstanding Shares: 129,472,000
  • Beta: 1.76
Profitability:
  • Net Margins: -526.72%
  • Return on Equity: -65.51%
  • Return on Assets: -44.09%
Debt:
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 5.70%
  • Quick Ratio: 5.70%
Additional Links:
Companies Related to Curis:

Analyst Ratings

Consensus Ratings for Curis (NASDAQ:CRIS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (92.31% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2016FBR & CoReiterated RatingBuyView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00View Rating Details
5/5/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
3/1/2016SunTrust Banks Inc.Initiated CoverageBuy$3.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details
7/6/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Curis (NASDAQ:CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.04)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.06)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Curis (NASDAQ:CRIS)
Current Year EPS Consensus Estimate: $-0.38 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.08)($0.05)($0.07)
Q2 20164($0.10)($0.05)($0.08)
Q3 20164($0.13)($0.07)($0.10)
Q4 20164($0.12)($0.07)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Curis (NASDAQ:CRIS)
Insider Ownership Percentage: 6.09%
Institutional Ownership Percentage: 52.36%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.20View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Curis (NASDAQ:CRIS)
DateHeadline
News IconCatching the Wonder of Investors: Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 30 at 4:51 PM
News IconIntraday Active Biotech Stocks News: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Curis, Inc. (NASDAQ:CRIS) - The Voice Registrar (NASDAQ:CRIS)
voiceregistrar.com - September 30 at 4:51 PM
News IconCuris, Inc. (CRIS) Updated Broker Price Targets - The De Soto Edge (NASDAQ:CRIS)
desotoedge.com - September 29 at 4:20 PM
News IconFeatured Stock: Curis, Inc. (NASDAQ:CRIS), Banco Bilbao Viscaya Argentaria S.A. (NYSE:BBVA) - Newburgh Press (NASDAQ:CRIS)
newburghpress.com - September 26 at 4:35 PM
News IconBiotech Stocks Worth a Closer Look: Curis, Inc. (NASDAQ:CRIS), Novavax, Inc. (NASDAQ:NVAX) - The Voice Registrar (NASDAQ:CRIS)
voiceregistrar.com - September 26 at 4:35 PM
4-traders.com logoCuris : Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement (NASDAQ:CRIS)
www.4-traders.com - September 25 at 4:01 PM
News IconBiotech Stocks Worth a Closer Look: Curis, Inc. (NASDAQ:CRIS), PDL BioPharma, Inc. (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:CRIS)
voiceregistrar.com - September 21 at 4:57 PM
News IconPenny Stock Investors Take an Interest in Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 21 at 8:39 AM
capitalcube.com logoETF’s with exposure to Curis, Inc. : September 19, 2016 (NASDAQ:CRIS)
www.capitalcube.com - September 19 at 5:12 PM
News IconInvestor's Watch: Curis, Inc. (NASDAQ:CRIS), Cara Therapeutics, Inc. (NASDAQ:CARA) - Newburgh Press (NASDAQ:CRIS)
newburghpress.com - September 19 at 9:06 AM
News IconIntraday Active Biotech Stocks News: Editas Medicine Inc. (NASDAQ:EDIT), Curis, Inc. (NASDAQ:CRIS) - The Voice Registrar (NASDAQ:CRIS)
voiceregistrar.com - September 19 at 9:06 AM
finance.yahoo.com logoCuris (CRIS) Shows Strength: Stock Adds 6.9% in Session (NASDAQ:CRIS)
finance.yahoo.com - September 19 at 9:06 AM
News IconKeen Investors Seek Information on Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 16 at 4:14 PM
publicnow.com logoCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:CRIS)
www.publicnow.com - September 16 at 4:14 PM
News IconStock Update, a Closer Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 15 at 4:48 PM
News IconNow Available: Checkpoint Surgical LLC - Medical Equipment - Deals and Alliances Profile (NASDAQ:CRIS)
reports.pr-inside.com - September 15 at 9:34 AM
News IconKeen Investors Narrowing Their Focus on Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 14 at 9:39 PM
News IconPlacing Curis, Inc. (NASDAQ:CRIS) Shares Under the Microscope - Post News (NASDAQ:CRIS)
www.kentuckypostnews.com - September 9 at 9:13 AM
News IconCuris, Inc. (NASDAQ:CRIS) From The Analysts Point of View - National Daily Press (NASDAQ:CRIS)
www.nationaldailypress.com - September 9 at 9:13 AM
News IconStock Showing Gains in Today's Session: Curis, Inc. (NASDAQ:CRIS) - Post News (NASDAQ:CRIS)
www.kentuckypostnews.com - September 8 at 8:10 AM
News IconRobert W. Baird Reiterates Outperform at Curis Inc. (NASDAQ: CRIS) - BNB Daily (blog) (NASDAQ:CRIS)
www.baseball-news-blog.com - September 8 at 8:10 AM
streetinsider.com logoCuris (CRIS) Partner Aurigene Discovery Receives 10.2M Shares at $2.40 in Lieu of Milestone Payment (NASDAQ:CRIS)
www.streetinsider.com - September 7 at 4:30 PM
News IconOTC Investors Supremely Interested in Shares of Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 7 at 7:13 AM
smarteranalyst.com logoCompany Update (NASDAQ:CRIS): Aurigene to Invest in Curis, Inc. at Premium Through Waiver of Certain Milestone ... - Smarter Analyst (NASDAQ:CRIS)
www.smarteranalyst.com - September 7 at 7:13 AM
finance.yahoo.com logo6:56 am Curis announces its collaborator, Aurigene Discovery Technologies, will receive 10.2 million shares of its common stock, priced at $2.40/share, (NASDAQ:CRIS)
finance.yahoo.com - September 7 at 7:13 AM
publicnow.com logoAurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement (NASDAQ:CRIS)
www.publicnow.com - September 7 at 7:13 AM
biz.yahoo.com logoCURIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Oth (NASDAQ:CRIS)
biz.yahoo.com - September 7 at 7:13 AM
News IconA Second Look at Shares of Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 2 at 4:11 PM
News IconUnder the Magnifying Glass: A Closer Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - September 1 at 4:20 PM
News IconTaking a Serious Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 31 at 4:39 PM
News IconZeroing Our Focus on Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 31 at 9:11 AM
finance.yahoo.com logoCuris to Present at Baird’s 2016 Global Healthcare Conference (NASDAQ:CRIS)
finance.yahoo.com - August 31 at 9:11 AM
publicnow.com logoQ2 2016 Curis Inc Earnings Conference Call (NASDAQ:CRIS)
www.publicnow.com - August 31 at 9:11 AM
capitalcube.com logoETF’s with exposure to Curis, Inc. : August 29, 2016 (NASDAQ:CRIS)
www.capitalcube.com - August 29 at 4:37 PM
News IconMagnifying Stocks of Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 23 at 4:32 PM
News IconLet's Take a Closer Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 23 at 8:37 AM
News IconPenny Stock Alert - Update & Review on This Stock: Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 19 at 8:30 PM
News IconInstitutions Have Decreased Their Ownership of Curis, Inc. (NASDAQ:CRIS) - Post News (NASDAQ:CRIS)
www.kentuckypostnews.com - August 19 at 3:30 PM
News IconCuris, Inc. (NASDAQ:CRIS) Shares in Focus According to the Crowd & Analysts - Post News (NASDAQ:CRIS)
www.kentuckypostnews.com - August 19 at 10:20 AM
News IconA Closer Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 16 at 9:42 PM
News IconSmall Cap Update on: Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS)
www.duncanindependent.com - August 15 at 11:40 AM
capitalcube.com logoETF’s with exposure to Curis, Inc. : August 15, 2016 (NASDAQ:CRIS)
www.capitalcube.com - August 15 at 11:40 AM
capitalcube.com logoCuris, Inc. :CRIS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:CRIS)
www.capitalcube.com - August 12 at 4:26 PM
finance.yahoo.com logoCURIS INC Financials (NASDAQ:CRIS)
finance.yahoo.com - August 11 at 4:32 PM
finance.yahoo.com logoEdited Transcript of CRIS earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:CRIS)
finance.yahoo.com - August 5 at 4:25 PM
seekingalpha.com logoCuris' (CRIS) CEO Ali Fattaey on Q2 2016 Results - Earnings Call Transcript (NASDAQ:CRIS)
seekingalpha.com - August 4 at 4:36 PM
rttnews.com logoEARNINGS SUMMARY: Details of Curis Inc Q2 Earnings Report (NASDAQ:CRIS)
www.rttnews.com - August 4 at 10:49 AM
globenewswire.com logoCuris Reports Second Quarter 2016 Financial Results (NASDAQ:CRIS)
globenewswire.com - August 4 at 10:49 AM
twst.com logoCuris Inc.: View all press releases » (NASDAQ:CRIS)
www.twst.com - August 4 at 10:49 AM
sg.finance.yahoo.com logoCuris reports 2Q loss (NASDAQ:CRIS)
sg.finance.yahoo.com - August 4 at 10:49 AM

Social

Curis (NASDAQ:CRIS) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff